Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 3425 - 3432 of 12093 results
Punching In: Biden’s DOL No. 2 Pick Su Faces Pressure From Right
February 16, 2021| News
Health Law Diagnosed — Final Rules Amending the Anti-Kickback Statute and Stark Law Regulations: Part 1
February 16, 2021| Podcast| Viewpoint
Legal Risks of Employer-Sponsored Covid-19 Workplace Vaccination Clinics
February 12, 2021| News
Webinar Recording: Navigating the Muddy Waters of the Supreme Court's Maui Decision
February 11, 2021| Webinar| Viewpoint
Despite EPA Guidance, Groundwater Permitting Decisions Remain Murky
February 11, 2021| News
Working Together, FDA, NTIA, and Domain Registries Take Down 30 Websites Illegally Selling Opioids
February 10, 2021| Blog| Viewpoint
New York State Department of Labor Updates Guidance on COVID-19 Leave Law
February 10, 2021| Blog| Viewpoint
MintzTech Connect: All Things Technology — February 2021
February 10, 2021| News
News & Press Releases
Mintz advised the creators of Morbid, one of the top-charting true crime podcasts, in a multi-year agreement to move to SiriusXM from Wondery. The deal gives SiriusXM exclusive advertising rights for the audio and video formats of the podcast.
Mintz Advises CVC DIF in Acquisition of SBA Communications’ Canadian Tower Infrastructure Platform
August 06, 2025
Mintz advised CVC DIF, the dedicated infrastructure investment strategy of global private markets manager CVC, in its agreement to acquire SBA Communications’ Canadian wireless tower business, one of Canada’s leading independent owners and operators of wireless communications towers. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions.
Mintz advised the underwriters in connection with a $69 million public offering by Larimar Therapeutics, Inc. of 21,562,500 shares of its common stock at a price to the public of $3.20 per share. The gross proceeds to Larimar from the offering were $69 million before deducting underwriting discounts and commissions and other offering expenses.
Events
Podcasts
Mintz On Air: Practical Policies - Investigations Unscripted
August 12, 2025| Podcast|
Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|
Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|